组别 | 安罗替尼同步放化疗 | 常规同步放化疗方案 | c2值 | P值 | ||
性别 | ||||||
男 | 14 | (66.67%) | 13 | (61.90%) | 1 | 0.872 |
女 | 7 | (33.33%) | 8 | (38.10%) | ||
中位年龄 | 62 | 65 | ||||
>50 | 5 | (23.81%) | 7 | (33.33%) | 1 | 0.881 |
<50 | 16 | (76.19%) | 14 | (66.67%) | ||
病变部位 | ||||||
颈段 | 3 | (14.29%) | 3 | (14.29%) | 1 | 0.765 |
胸上段 | 5 | (23.81%) | 6 | (28.57%) | ||
胸中段 | 9 | (42.86%) | 7 | (33.33%) | ||
胸下段 | 4 | (19.05%) | 5 | (23.81%) | ||
病变长度(cm) | 5.7 ± 1.3 | 5.4 ± 1.5 | —— | 0.821 | ||
分化程度 | ||||||
高 | 4 | (19.05%) | 6 | (28.57%) | 1 | 0.698 |
中 | 10 | (47.62%) | 9 | (42.86%) | ||
低 | 7 | (33.33%) | 6 | (28.57%) | ||
TNM分期 | ||||||
II期 | 9 | (42.86%) | 10 | (47.62%) | 1 | 0.631 |
III期(除T4) | 12 | (57.14%) | 11 | (52.38%) | ||
ECOG评分 | ||||||
0 | 6 | (28.57%) | 7 | (33.33%) | 1 | 0.664 |
1 | 11 | (52.38%) | 10 | (47.62%) | ||
2 | 4 | (19.05%) | 4 | (19.05%) |